Content
10/03/2023
San Diego, CA USA
Cortica
completed $40 million Series D Round funding. Investors include
CVS Health Ventures (lead), Ascension Ventures, LRVHealth.
About
About
Cortica is a rapidly growing healthcare company pioneering a unique and effective approach to treating neurodevelopmental conditions including autism spectrum disorder, speech and language delays, sensory processing disorder and other conditions that impact brain development. Harnessing insights and technologies from emerging neuroscience, Cortica brings together clinical specialists from a range of disciplines to design and deliver comprehensive care to children with developmental differences.
Cortica's treatment model coordinates a multidisciplinary team of clinicians with the common goals of fostering the child's holistic development and empowering family members. An “inside out” component focuses on improving the health of the body through medical diagnosis and treatment, nutrition, supplements, neurofeedback, and other strategies. Simultaneously, an “outside-in” component optimizes the environment, learning opportunities, and overall experiences of the child through speech and language therapy, neurological music therapy, occupational therapy, a progressive model of Applied Behavioral Analysis, and parent education.
More than simply bringing these services under one roof, specialists at Cortica collaborate to achieve a common understanding of each patient, develop individually tailored treatment plans, and coordinate care that evolves to match the child's progress.
Startup
Sector:
Healthcare
Download StockFan App
Ad
Stock market data, news and community, all integrated.
Features include real time stock quotes, interactive charts, technical signals, institutional & insider ownerships, stock screener, ETF rankings, SEC filings, press releases, videos, earnings calendar, social media posts, group chats.
